Immune activation mediated change in alpha-1-acid glycoprotein: Impact on total and free lopinavir plasma exposure

Journal of Clinical Pharmacology

Volumn 51, Issue 11, 2011, Pages 1539-1548

  Ofotokun, Ighovwerha ^a   Lennox, Jeffrey L ^a   Eaton, Molly E ^a   Ritchie, James C ^a   Easley, Kirk A ^b   Masalovich, Svetlana E ^b   Long, Mary C ^c   Acosta, Edward P ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

antiretroviral drugs; pharmacokinetics; protein binding

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; OROSOMUCOID; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSTIMULATION; MALE; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STEADY STATE;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; OROSOMUCOID; PROSPECTIVE STUDIES; PROTEIN BINDING; RITONAVIR; RNA, VIRAL;

EID: 80054767687     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010385118     Document Type: Article

References (29)

1. Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular, and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS. 2004 ; 18: 1305-1310 (Pubitemid 38822709)
2. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002 ; 16: 551-560 (Pubitemid 34218850)
3. Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)-a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr. 2006 ; 41: 461-467
4. Masquelier B, Breilh D, Neau D, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2002 ; 46: 2926-2932
5. Monforte A, Leprib A, Rezzac G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS. 2000 ; 14: 499-507 (Pubitemid 30209692)
6. Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci. 1982 ; 389: 39-48 (Pubitemid 12013176)
7. Bree F, Houin G, Barre J, et al. Pharmacokinetics of intravenously administered 125I-labelled human alpha-1-acid glycoprotein. Clin Pharmacokinet. 1986 ; 11: 336-342 (Pubitemid 16044237)
8. Urien S, Barré J, Morin C, Paccaly A, Montay G, Tillement JP. Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein. Investig. New Drug. 1996 ; 14: 147-151 (Pubitemid 26340683)
9. Bohte R, Mattie H, van den Broek PJ. Levels of azithromycin and alpha-1-acid glycoprotein in serum in patients with community-acquired pneumonia. Antimicrob Agents Chemother. 1995 ; 39: 2801-2802
10. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev. 2001 ; 33: 161-235 (Pubitemid 32703255)
11. Jones K, Hoggard PG, Khoo S, Maher B, Back DJ. Effect of a-1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors SQV, ritonavir, and IDV in vitro. Br J ClinPharmacol. 2001 ; 51: 99-102 (Pubitemid 32118826)
12. Zhang XQ, Schooley RT, Gerber JG. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. J Infect Dis. 1999 ; 180: 1833-1837
13. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Published December 2009. Accessed April 7, 2010.
14. AssayPro Human alpha1-acid Glycoprotein ELISA Kit. http://www.assaypro. com/msdselisa-test.asp. Accessed July 29, 2010.
15. Ofotokun I, Chuck SK, Binongo JN, Palau M, Lennox JL, Acosta EP. Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol. 2007 ; 47: 970-977 (Pubitemid 47094097)
16. Micheli V, Regazzi M, Dickinson L, et al. Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis. Ther Drug Monit. 2008 ; 30: 306-313
17. Pruessner J, Kirschbaum C, Meinlschmid G, Hellhammer D. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology. 2003 ; 28: 916-931 (Pubitemid 36936799)
18. Stellrecht K, Drusano GL, Stein DS, Bilello JA. Plasma alpha-1-acid glycoprotein is reduced in HIV-infected patients coinfected with hepatitis C virus (HCV). Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections ; Washington, DC ;..
19. Flaherty JF, Gatti G, White J, Bubp J, Borin M, Gambertoglio JG. Protein binding of clindamycin in sera of patients with AIDS. Antimicrob. Agents Chemother. 1996 ; 40: 1134-1138 (Pubitemid 26136022)
20. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003 ; 187: 1534-1543 (Pubitemid 36578959)
21. Fabbiani M, Di Giambenedetto S, Bracciale L, et al. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother. 2009 ; 64: 109-117
22. Lin JH. Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. Curr Drug Metab. 2007 ; 8: 109-136 (Pubitemid 46218679)
23. King JR, Gerber JG, Fletcher CV, Bushman L, Acosta EP. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. AIDS. 2005 ; 19: 1059-1063 (Pubitemid 40961146)
24. Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002 ; 71: 115-121 (Pubitemid 34271114)
25. Best BM, Goicoechea M, Witt MD, et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007 ; 46: 433-442 (Pubitemid 350098694)
26. Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS. 2002 ; 16: 2311-2315 (Pubitemid 35449017)
27. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006 ; 20: 1931-1939 (Pubitemid 44427610)
28. van der Lugt J, Colbers A, Burger D. Clinical pharmacology of HIV protease inhibitors in pregnancy. Curr Opin HIV AIDS. 2008 ; 3: 620-626
29. Boffito M, Hoggard PG, Lindup WE, et al. Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit. 2004 ; 26: 35-39 (Pubitemid 38140908)